Ironwood Pharmaceuticals (IRWD) Receivables (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Receivables data on file, last reported at $105.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 165.93% year-over-year to $105.8 million; the trailing twelve-month figure through Mar 2026 stood at $105.8 million (up 165.93% YoY), and the FY2025 full-year result was $46.7 million, down 42.98% from the prior year.
• Receivables improved to $105.8 million in Q1 2026, from $46.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $131.0 million in Q3 2022 to a low of $39.8 million in Q1 2025.
• A 5-year average of $98.4 million and a median of $115.7 million in 2023 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 51.17% in 2024 and jumped 165.93% in 2026, its largest moves.
• Tracing IRWD's Receivables over 5 years: stood at $130.0 million in 2022, then retreated by 0.69% to $129.1 million in 2023, then sank by 36.56% to $81.9 million in 2024, then sank by 42.98% to $46.7 million in 2025, then jumped by 126.64% to $105.8 million in 2026.
• Business Quant data shows IRWD's Receivables at $105.8 million in Q1 2026, $46.7 million in Q4 2025, and $120.4 million in Q3 2025.